Safety
In patients with aNSCLC,
Optune Lua with IOs or docetaxel did not add any systemic toxicities vs IOs or docetaxel alone1
Most frequently reported AEs2
- In the pivotal trial, the most frequently reported AEs aside from dermatitis were those associated with the systemic therapies or with the disease itself and include: fatigue (33%), musculoskeletal pain (32%), anemia (23%), dyspnea (23%), cough (19%), diarrhea (19%), leukopenia (17%), and nausea (17%)
Most discontinuations were due to progression of disease3.
- Optune Lua-related AEs led to discontinuation in 12% of patients in the Optune Lua + IO arm and 17% in the Optune Lua + docetaxel arm
Dermatologic AEs were the only device-related AEs observed in >5% of patients3
- Total rate of Optune Lua-related AEs was 73% in the Optune Lua + IO arm and 70% in the Optune Lua + docetaxel arm3
- Mild-to-moderate (grades 1 and 2) skin irritation was the most common device-related side effect3
The skin irritation improved with use of topical corticosteroids1,*
- In persistent cases, the condition resolved with the use of low-dose oral corticosteroids1
- Regular relocation of the transducer arrays was necessary to allow for continuous treatment1
- Only 8 patients (6%) reported a grade 3 Optune Lua–related AE, most of which were local to the skin2,3
- There were no grade 4 toxicities or deaths attributed to Optune Lua2,3
*In the EF-15 pilot study.1
See quality of life data in aNSCLC patients
AE, adverse event; aNSCLC, advanced non-small cell lung cancer; IO, immuno-oncology agent (nivolumab, pembrolizumab, or atezolizumab).
References: 1. Optune Lua. Instructions for Use for non small cell lung cancer. Novocure; 2023. 2. Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023;24(9):1002-1017. doi:10.1016/S1470-2045(23)00344-3 3. Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Supplementary appendix. Lancet Oncol. 2023;24(9):1002-1017. doi:10.1016/S1470-2045(23)00344-3